Possible long-term effects of γ-hydroxybutyric acid (GHB) due to neurotoxicity and overdose

Neuroscience and Biobehavioral Reviews

Volumn 36, Issue 4, 2012, Pages 1217-1227

  van Amsterdam, Jan G C ^a   Brunt, Tibor M ^b   McMaster, Minni T B ^b   Niesink, Raymond J M ^b,c  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b NETHERLANDS INSTITUTE OF MENTAL HEALTH AND ADDICTION   (Netherlands)

^c OPEN UNIVERSITY OF THE NETHERLANDS   (Netherlands)

Author keywords

Cognition; Gamma hydroxybutyric acid; GHB; Neurotoxicity; Party drugs; Recreational drugs

Indexed keywords

4 HYDROXYBUTYRIC ACID; ALCOHOL; ANESTHETIC AGENT; BENZODIAZEPINE; ISOFLURANE; KETAMINE; PROPOFOL; SEDATIVE AGENT;

BEHAVIOR DISORDER; BINGE DRINKING; BRAIN MATURATION; COGNITION; COMA; DRUG DEPENDENCE; DRUG EFFECT; DRUG MEGADOSE; DRUG MISUSE; DRUG OVERDOSE; HUMAN; LOW DRUG DOSE; MEMORY; NETHERLANDS; NEUROTOXICITY; NONHUMAN; PRIORITY JOURNAL; RECREATION; REPEATED DRUG DOSE; REVIEW;

ALCOHOLISM; ANESTHETICS; ANESTHETICS, DISSOCIATIVE; ANIMALS; CENTRAL NERVOUS SYSTEM DEPRESSANTS; COGNITION DISORDERS; COMA; ETHANOL; GLUTAMIC ACID; HUMANS; KETAMINE; NEUROTOXICITY SYNDROMES; OVERDOSE; OXIDATIVE STRESS; SODIUM OXYBATE; STREET DRUGS; SUBSTANCE WITHDRAWAL SYNDROME; SUBSTANCE-RELATED DISORDERS; SUCCINATE-SEMIALDEHYDE DEHYDROGENASE;

EID: 84857388905     PISSN: 01497634     EISSN: 18737528     Source Type: Journal    
DOI: 10.1016/j.neubiorev.2012.02.002     Document Type: Review

References (159)

1. Aasebo I.E., Blankvoort S., Tashiro A. Critical maturational period of new neurons in adult dentate gyrus for their involvement in memory formation. Eur. J. Neurosci. 2011, 33:1094-1100.
2. Abad M.A., Enguita M., gregorio-Rocasolano N., Ferrer I., Trullas R. Neuronal pentraxin 1 contributes to the neuronal damage evoked by amyloid-beta and is overexpressed in dystrophic neurites in Alzheimer's brain. J. Neurosci. 2006, 26:12735-12747.
3. Abanades S., Farre M., Barral D., Torrens M., Closas N., Langohr K., Pastor A., de la T.R. Relative abuse liability of gamma-hydroxybutyric acid, flunitrazepam, and ethanol in club drug users. J. Clin. Psychopharmacol. 2007, 27:625-638.
4. Abanades S., Farre M., Segura M., Pichini S., Barral D., Pacifici R., Pellegrini M., Fonseca F., Langohr K., de la T.R. Gamma-hydroxybutyrate (GHB) in humans: pharmacodynamics and pharmacokinetics. Ann. N. Y. Acad. Sci. 2006, 1074:559-576.
5. Allen R.M., Young S.J. Phencyclidine-induced psychosis. Am. J. Psychiatry 1978, 135:1081-1084.
6. Andriamampandry C., Taleb O., Kemmel V., Humbert J.P., Aunis D., Maitre M. Cloning and functional characterization of a gamma-hydroxybutyrate receptor identified in the human brain. FASEB J. 2007, 21:885-895.
7. Andriamampandry C., Taleb O., Viry S., Muller C., Humbert J.P., Gobaille S., Aunis D., Maitre M. Cloning and characterization of a rat brain receptor that binds the endogenous neuromodulator gamma-hydroxybutyrate (GHB). FASEB J. 2003, 17:1691-1693.
8. Barker J.C., Karsoho H. Hazardous use of gamma hydroxybutyrate: driving under the influence. Subst. Use Misuse 2008, 43:1507-1520.
9. Bernasconi R., Mathivet P., Otten V., Bettler B., Bischoff S., Marescaux C. Part of the pharmacological actions of gammahydroxybutyrate are mediated by GABAB receptors. Gammahydroxybutyrate: Molecular. Functional and Clinical Aspects 2002, 28-63. Taylor & Francis, New York. G. Tunnicliff, C.D. Cash (Eds.).
10. Berton F., Brancucci A., Beghe F., Cammalleri M., Demuro A., Francesconi W., Gessa G.L. Gamma-hydroxybutyrate inhibits excitatory postsynaptic potentials in rat hippocampal slices. Eur. J. Pharmacol. 1999, 380:109-116.
11. Black J., Pardi D., Hornfeldt C.S., Inhaber N. The nightly administration of sodium oxybate results in significant reduction in the nocturnal sleep disruption of patients with narcolepsy. Sleep Med. 2009, 10:829-835.
12. Bossong M.G., Niesink R.J. Adolescent brain maturation, the endogenous cannabinoid system and the neurobiology of cannabis-induced schizophrenia. Prog. Neurobiol. 2010, 92:370-385.
13. Brown S.A., Tapert S.F., Granholm E., Delis D.C. Neurocognitive functioning of adolescents: effects of protracted alcohol use. Alcohol Clin. Exp. Res. 2000, 24:164-171.
14. Brown S.A., Tapert S.F., Granholm E., Delis D.C. Neuro-cognitive functioning of adolescents: effects of protracted alcohol use. Alcohol Clin. Exp. Res. 2000, 24:164-171.
15. Busl K.M., Greer D.M. Hypoxic-ischemic brain injury: pathophysiology, neuropathology and mechanisms. NeuroRehabilitation 2010, 26:5-13.
16. Bustos G., Kuhar M.J., Roth R.H. Effect of gamma-hydroxybutyrate and gamma-butyrolactone on dopamine synthesis and uptake by rat striatum. Biochem. Pharmacol. 1972, 21:2649-2652.
17. Camacho A., Matthews S.C., Murray C.F., Dimsdale J.E. Use of GHB compounds among college students. Am. J. Drug Alcohol Abuse 2005, 31:6001-6607.
18. Caputo F., Vignoli T., Maremmani I., Bernardi M., Zoli G. Gamma hydroxybutyric acid (GHB) for the treatment of alcohol dependence: a review. Int. J. Environ. Res. Public Health 2009, 6:1917-1929.
19. Carter L.P., Koek W., France Ch.P. Lack of effects of GHB precursors GBL and 1,4-BD following i.c.v. administration in rats. Eur. J. Neurosci. 2006, 24:2595-2600.
20. Carter L.P., Griffiths R.R., Mintzer M.Z. Cognitive, psychomotor, and subjective effects of sodium oxybate and triazolam in healthy volunteers. Psychopharmacology (Berl) 2009, 206:141-154.
21. Carter L.P., Pardi D., Gorsline J., Griffiths R.R. Illicit gamma-hydroxybutyrate (GHB) and pharmaceutical sodium oxybate (Xyrem): differences in characteristics and misuse. Drug Alcohol Depend. 2009, 104:1-10.
22. Cash C.D., Tunnicliff G. The gammahydroxybutyrate recepto. Gammahydroxybutyrate: Molecular, Functional and Clinical Aspects 2002, 17-27. Taylor & Francis, New York. B. the, G. in: Tunnicliff, C.D. Cash (Eds.).
23. Castelli M.P., Ferraro L., Mocci I., Carta F., Carai M.A., Antonelli T., Tanganelli S., Cignarella G., Gessa G.L. Selective gamma-hydroxybutyric acid receptor ligands increase extracellular glutamate in the hippocampus, but fail to activate G protein and to produce the sedative/hypnotic effect of gamma-hydroxybutyric acid. J. Neurochem. 2003, 87:722-732.
24. Cervos-Navarro J., Diemer N.H. Selective vulnerability in brain hypoxia. Crit. Rev. Neurobiol. 1991, 6:149-182.
25. Chambliss K.L., Hinson D.D., Trettel F., Malaspina P., Novelletto A., Jakobs C., Gibson K.M. Two exon-skipping mutations as the molecular basis of succinic semialdehyde dehydrogenase deficiency (4-hydroxybutyric aciduria). Am. J. Hum. Genet. 1998, 63:399-408.
26. Cosgrove J., Newell T.G. Recovery of neuropsychological functions during reduction in use of phencyclidine. J. Clin. Psychol. 1991, 47:159-169.
27. Craig K., Gomez H.F., McManus J.L., Bania T.C. Severe gamma-hydroxybutyrate withdrawal: a case report and literature review. J. Emerg. Med. 2000, 18:65-70.
28. Culley D.J., Baxter M.G., Yukhananov R., Crosby G. Long-term impairment of acquisition of a spatial memory task following isoflurane-nitrous oxide anesthesia in rats. Anesthesiology 2004, 100:309-314.
29. Curran H.V., Morgan C. Cognitive, dissociative and psychotogenic effects of ketamine in recreational users on the night of drug use and 3 days later. Addiction 2000, 95:575-590.
30. De Gregorio-Rocasolano N., Gasull T., Trullas R. Overexpression of neuronal pentraxin 1 is involved in neuronal death evoked by low K(+) in cerebellar granule cells. J. Biol. Chem. 2001, 276:796-803.
31. de Jong C.A.J., Kamal R., Dijkstra B.A.G., de Haan H.A. Gamma-hydroxybutyrate detoxification by titration and tapering. Eur. Addict. Res. 2012, 18:40-45.
32. Degenhardt L., Darke S., Dillon P. GHB use among Australians: characteristics, use patterns and associated harm. Drug Alcohol Depend. 2002, 67:89-94.
33. Degenhardt L., Darke Sh Dillon P. The prevalence and correlates of gamma-hydroxybutyrate (GHB) overdose among Australian users. Addiction 2003, 98:199-204.
34. Degenhardt L., Dunn M. The epidemiology of GHB and ketamine use in an Australian household survey. Int. J. Drug Policy 2008, 19:311-316.
35. Devlin R.J., Henry J.A. Clinical review: major consequences of illicit drug consumption. Crit. Care 2008, 12:202.
36. Di P.M., Caltagirone C., Fadda L., Sabatini U., Serra L., Carlesimo G.A. Hippocampal atrophy is the critical brain change in patients with hypoxic amnesia. Hippocampus 2008, 18:719-728.
37. Diana M., Mereu G., Mura A., Fadda F., Passino N., Gessa G. Low doses of gamma-hydroxybutyric acid stimulate the firing rate of dopaminergic neurons in unanesthetized rats. Brain Res. 1991, 566:208-211.
38. Dietze P.M., Cvetkovski S., Barratt M.J., Clemens S. Patterns and incidence of gamma-hydroxybutyrate (GHB)-related ambulance attendances in Melbourne, Victoria. Med. J. Aust. 2008, 188:709-711.
39. Dimitrijevic N., Dzitoyeva S., Satta R., Imbesi M., Yildiz S., Manev H. Drosophila GABA(B) receptors are involved in behavioral effects of gamma-hydroxybutyric acid (GHB). Eur. J. Pharmacol. 2005, 519:246-252.
40. Dyer J.E., Roth B., Hyma B.A. Gamma-hydroxybutyrate withdrawal syndrome. Ann. Emerg. Med. 2001, 37:147-153.
41. Felmlee M.A., Wang Q., Cui D., Roiko S.A., Morris M.E. Mechanistic toxicokinetic model for gamma-hydroxybutyric acid: inhibition of active renal reabsorption as a potential therapeutic strategy. AAPS J. 2010, 12:407-416.
42. Fernandes J.S., Mori M.A., Ekuni R., Oliveira R.M., Milani H. Long-term treatment with fish oil prevents memory impairments but not hippocampal damage in rats subjected to transient, global cerebral ischemia. Nutr. Res. 2008, 28:798-808.
43. Ferraro L., Tanganelli S., O'Connor W.T., Francesconi W., Loche A., Gessa G.L., Antonelli T. Gamma-hydroxybutyrate modulation of glutamate levels in the hippocampus: an in vivo and in vitro study. J. Neurochem. 2001, 78:929-939.
44. Fountoulakis M., Juranville J.F., Berndt P., Langen H., Suter L. Two-dimensional database of mouse liver proteins. An update. Electrophoresis 2001, 22:1747-1763.
45. Fredriksson A., Ponten E., Gordh T., Eriksson P. Neonatal exposure to a combination of N-methyl-d-aspartate and gamma-aminobutyric acid type A receptor anesthetic agents potentiates apoptotic neurodegeneration and persistent behavioral deficits. Anesthesiology 2007, 107:427-436.
46. Freese T.E., Miotto K., Reback C.J. The effects and consequences of selected club drugs. J. Subst. Abuse Treat. 2002, 23:151-156.
47. Friedman J., Westlake R., Furman M. Grievous bodily harm: gamma hydroxybutyrate abuse leading to a Wernicke-Korsakoff syndrome. Neurology 1996, 46:469-471.
48. Galicia M., Nogue S., Miró O. Liquid ecstasy intoxication: clinical features of 505 consecutive emergency department patients. Emerg. Med. J. 2011, 28:462-466.
49. Galloway G.P., Frederick S.L., Staggers F.E., Gonzáles M., Stalcup S.A., Smith D.E. GHB: an emerging drug of abuse that causes physical dependence. Addiction 1997, 92:89-96.
50. Gibson K.M., Christensen E., Jakobs C., Fowler B., Clarke M.A., Hammersen G., Raab K., Kobori J., Moosa A., Vollmer B., Rossier E., Iafolla A.K., Matern D., Brouwer O.F., Finkelstein J., Aksu F., Weber H.P., Bakkeren J.A., Gabreels F.J., Bluestone D., Barron T.F., Beauvais P., Rabier D., Santos C., Lehnert W. The clinical phenotype of succinic semialdehyde dehydrogenase deficiency (4-hydroxybutyric aciduria): case reports of 23 new patients. Pediatrics 1997, 99:567-574.
51. Gibson K.M., Gupta M., Pearl P.L., Tuchman M., Vezina L.G., Snead O.C., Smit L.M., Jakobs C. Significant behavioral disturbances in succinic semialdehyde dehydrogenase (SSADH) deficiency (gamma-hydroxybutyric aciduria). Biol. Psychiatry 2003, 54:763-768.
52. Gill J.S. Reported levels of alcohol consumption and binge drinking within the UK undergraduate student population over the last 25 years. Alcohol Alcohol. 2002, 37:109-120.
53. Gobaille S., Hechler V., Andriamampandry C., Kemmel V., Maitre M. Gamma-hydroxybutyrate modulates synthesis and extracellular concentration of gamma-aminobutyric acid in discrete rat brain regions in vivo. J. Pharmacol. Exp. Ther. 1999, 290:303-309.
54. Gonzalez A., Nutt D.J. Gamma hydroxy butyrate abuse and dependency. J. Psychopharmacol. 2005, 19:195-204.
55. Goodwin A.K., Griffiths R.R., Brown P.R., Froestl W., Jakobs C., Gibson K.M., Weerts E.M. Chronic intragastric administration of gamma-butyrolactone produces physical dependence in baboons. Psychopharmacol (Berl.) 2006, 189:71-82.
56. Goodwin A.K., Kaminski B.J., Griffiths R.R., Ator N.A., Weerts E.M. Intravenous self-administration of gamma-hydroxybutyrate (GHB) in baboons. Drug Alcohol Depend. 2011, 114:217-224.
57. Hanson K.L., Medina K.L., Padula C.B., Tapert S.F., Brown S.A. Impact of adolescent alcohol and drug use on neuropsychological functioning in young adulthood: 10-year outcomes. J. Child Adolesc. Subst. Abuse 2011, 20:135-154.
58. Hayes J.D., Flanagan J.U., Jowsey I.R. Glutathione transferases. Annu. Rev. Pharmacol. Toxicol. 2005, 45:51-88.
59. Hechler V., Gobaille S., Bourguignon J.J., Maitre M. Extracellular events induced by gamma-hydroxybutyrate in striatum: a microdialysis study. J. Neurochem. 1991, 56:938-944.
60. Hechler V., Gobaille S., Maitre M. Selective distribution pattern of gamma-hydroxybutyrate receptors in the rat forebrain and midbrain as revealed by quantitative autoradiography. Brain Res. 1992, 572:345-348.
61. Hechler V., Ratomponirina C., Maitre M. Gamma-hydroxybutyrate conversion into GABA induces displacement of GABAB binding that is blocked by valproate and ethosuximide. J. Pharmacol. Exp. Ther. 1997, 281:753-760.
62. Heffernan T.M., Bartholomew J. Does excessive alcohol use in teenagers affect their everyday prospective memory?. J. Adolesc. Health 2006, 39:138-140.
63. Hemmings H.C., Akabas M.H., Goldstein P.A., Trudell J.R., Orser B.A., Harrison N.L. Emerging molecular mechanisms of general anesthetic action. Trends Pharmacol. Sci. 2005, 26:503-510.
64. Hernandez M., McDaniel C.H., Costanza C.D., Hernandez O.J. GHB-induced delirium: a case report and review of the literature of gamma hydroxybutyric acid. Am. J. Drug Alcohol Abuse 1998, 24:179-183.
65. Hossmann K.A. The hypoxic brain. Insights from ischemia research. Adv. Exp. Med. Biol. 1999, 474:155-169.
66. Howland J., Rohsenow D.J., Greece J.A., Littlefield C.A., Almeida A., Heeren T., Winter M., Bliss C.A., Hunt S., Hermos J. The effects of binge drinking on college students' next-day academic test-taking performance and mood state. Addiction 2010, 105:655-665.
67. Ikonomidou C., Bosch F., Miksa M., Bittigau P., Vockler J., Dikranian K., Tenkova T.I., Stefovska V., Turski L., Olney J.W. Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain. Science 1999, 283:70-74.
68. Jessberger S., Clark R.E., Broadbent N.J., Clemenson G.D., Consiglio A., Lie D.C., Squire L.R., Gage F.H. Dentate gyrus-specific knockdown of adult neurogenesis impairs spatial and object recognition memory in adult rats. Learn. Mem. 2009, 16:147-154.
69. Kam P.C., Yoong F.F. Gamma-hydroxybutyric acid: an emerging recreational drug. Anaesthesia 1998, 53:1195-1198.
70. Kamiyama H., Matsumoto M., Otani S., Kimura S.I., Shimamura K.I., Ishikawa S., Yanagawa Y., Togashi H. Mechanisms underlying ketamine-induced synaptic depression in rat hippocampus-medial prefrontal cortex pathway. Neuroscience 2011, 177:159-169.
71. Kelly B.C., Parsons J.T., Wells B.E. Prevalence and predictors of club drug use among club-going young adults in New York city. J. Urban Health 2006, 83:884-895.
72. Kemmel V., Klein C., Dembele D., Jost B., Taleb O., Aunis D., Mensah-Nyagan A.G., Maitre M. A single acute pharmacological dose of gamma-hydroxybutyrate (GHB) modifies multiple gene expression patterns in rat hippocampus and frontal cortex. Physiol. Genomics 2010, Epub ahead of print.
73. Kim S.Y., Anderson I.B., Dyer J.E., Barker J.C., Blanc P.D. High-risk behaviors and hospitalizations among gamma hydroxybutyrate (GHB) users. Am. J. Drug Alcohol Abuse 2007, 33:429-438.
74. Klein C., Kemmel V., Taleb O., Aunis D., Maitre M. Pharmacological doses of gamma-hydroxybutyrate (GHB) potentiate histone acetylation in the rat brain by histone deacetylase inhibition. Neuropharmacology 2009, 57:137-147.
75. Kleinschmidt S., Mertzlufft F. Gamma-hydroxybutyric acid-significance for anesthesia and intensive care medicine?. Anasthesiol. Intensivmed. Notfallmed. Schmerzther. 1995, 30:393-402.
76. Knerr I., Gibson K.M., Ganesh J., Bennett M.J., Salomons G.S., Jakobs C., Myers S.M. Diagnostic challenges in a severely delayed infant with hypersomnolence, failure to thrive and arteriopathy: a unique case of gamma-hydroxybutyric aciduria and Williams syndrome. Am. J. Med. Genet. B: Neuropsychiatr. Genet. 2007, 144B:946-948.
77. Knerr I., Gibson K.M., Jakobs C., Pearl P.L. Neuropsychiatric morbidity in adolescent and adult succinic semialdehyde dehydrogenase deficiency patients. CNS Spectr. 2008, 13:598-605.
78. Knudsen K., Jonsson U., Abrahamsson J. Twenty-three deaths with gamma-hydroxybutyrate overdose in western Sweden between 2000 and 2007. Acta Anaesthesiol. Scand. 2010, 54:987-992.
79. Koek W., France C.P. Cataleptic effects of gamma-hydroxybutyrate (GHB) and baclofen in mice: mediation by GABA(B) receptors, but differential enhancement by N-methyl-d-aspartate (NMDA) receptor antagonists. Psychopharmacology (Berl.) 2008, 199:191-198.
80. Krasowski M.D., Koltchine V.V., Rick C.E., Ye Q., Finn S.E., Harrison N.L. Propofol and other intravenous anesthetics have sites of action on the gamma-aminobutyric acid type A receptor distinct from that for isoflurane. Mol. Pharmacol. 1998, 53:530-538.
81. Krul J., Girbes A.R.J. Gamma-hydroxybutyrate: experience of 9 years of gamma-hydroxybutyrate (GHB)-related incidents during rave parties in The Netherlands. Clin. Toxicol. 2011, 49:311-315.
82. Kueh D., Iwamoto K., Poling A., Baker L.E. Effects of gamma-hydroxybutyrate (GHB) and its metabolic precursors on delayed-matching-to-position performance in rats. Pharmacol. Biochem. Behav. 2008, 89:179-187.
83. Laborit H. Sodium 4-hydroxybutyrate. Int. J. Neuropharmacol. 1964, 3:433-451.
84. Latini A., Scussiato K., Leipnitz G., Gibson K.M., Wajner M. Evidence for oxidative stress in tissues derived from succinate semialdehyde dehydrogenase-deficient mice. J. Inherit. Metab. Dis. 2007, 30:800-810.
85. Li Q., Kuhn C.M., Wilson W.A., Lewis D.V. Effects of gamma hydroxybutyric acid on inhibition and excitation in rat neocortex. Neuroscience 2007, 150:82-92.
86. Liechti M.E., Kunz I., Greminger P., Speich R., Kupferschmidt H. Clinical features of gamma-hydroxybutyrate and gamma-butyrolactone toxicity and concomitant drug and alcohol use. Drug Alcohol Dep. 2006, 81:323-326.
87. Loepke A.W., Istaphanous G.K., McAuliffe J.J., Miles L., Hughes E.A., McCann J.C., Harlow K.E., Kurth C.D., Williams M.T., Vorhees C.V., Danzer S.C. The effects of neonatal isoflurane exposure in mice on brain cell viability, adult behavior, learning, and memory. Anesth. Analg. 2009, 108:90-104.
88. Loepke A.W., Soriano S.G. An assessment of the effects of general anesthetics on developing brain structure and neurocognitive function. Anesth. Analg. 2008, 106:1681-1707.
89. Lopez-Fanarraga M., Carranza G., Bellido J., Kortazar D., Villegas J.C., Zabala J.C. Tubulin cofactor B plays a role in the neuronal growth cone. J. Neurochem. 2007, 100:1680-1687.
90. Maitre M. The gamma-hydroxybutyrate signalling system in brain: organization and functional implications. Prog. Neurobiol. 1997, 51:337-361.
91. Malaspina P., Picklo M.J., Jakobs C., Snead O.C., Gibson K.M. Comparative genomics of aldehyde dehydrogenase 5a1 (succinate semialdehyde dehydrogenase) and accumulation of gamma-hydroxybutyrate associated with its deficiency. Hum. Genomics 2009, 3:106-120.
92. Mamelak M. Alzheimer's disease, oxidative stress and gammahydroxybutyrate. Neurobiol. Aging 2007, 28:1340-1360.
93. McDonough M., Kennedy N., Glasper A., Bearn J. Clinical features and management of gamma-hydroxybutyrate (GHB) withdrawal: a review. Drug Alcohol Depend. 2004, 75:3-9.
94. Miotto K., Darakjian J., Basch J., Murray S., Zogg J., Rawson R. Gamma-hydroxybutyric acid. Patterns of use, effects and withdrawal. Am. J. Addict. 2001, 10:232-241.
95. Miyamoto O., Auer R.N. Hypoxia, hyperoxia, ischemia, and brain necrosis. Neurology 2000, 54:362-371.
96. Moller J.T., Cluitmans P., Rasmussen L.S., Houx P., Rasmussen H., Canet J., Rabbitt P., Jolles J., Larsen K., Hanning C.D., Langeron O., Johnson T., Lauven P.M., Kristensen P.A., Biedler A., van B.H., Fraidakis O., Silverstein J.H., Beneken J.E., Gravenstein J.S. Long-term postoperative cognitive dysfunction in the elderly ISPOCD1 study. ISPOCD investigators. International Study of Post-Operative Cognitive Dysfunction. Lancet 1998, 351:857-861.
97. Morgan C.J., Curran H.V. Ketamine use: a review. Addiction 2011, 107:27-38.
98. Morgan C.J.A., Curran H.V. Acute and chronic effects of ketamine upon human memory: a review. Psychopharmacology (Berl.) 2006, 188:408-424.
99. Morgan C.J.A., Muetzelfeldt L., Curran H.V. Ketamine use, cognition and psychological wellbeing: a comparison of frequent, infrequent and ex-users with polydrug and non-using controls. Addiction 2009, 104:77-87.
100. Morgan C.J.A., Muetzelfeldt L., Curran H.V. Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study. Addiction 2010, 105:121-133.
101. Morgan C.J.A., Riccelli M., Maitland C.H., Curran H.V. Long-term effects of ketamine: evidence for a persisting impairment of source memory in recreational users. Drug Alcohol Depend. 2004, 75:301-308.
102. Morrell M.J., Twigg G. Neural consequences of sleep disordered breathing: the role of intermittent hypoxia. Adv. Exp. Med. Biol. 2006, 588:75-88.
103. Munir V.L., Hutton J.E., Harney J.P., Buykx P., Weiland T.J., Dent A.W. Gamma-hydroxybutyrate: a 30 month emergency department review. Emerg. Med. Australas. 2008, 20:521-530.
104. Nasrallah F.A., Maher A.D., Hanrahan J.R., Balcar V.J., Rae C.D. Gamma-hydroxybutyrate and the GABAergic footprint: a metabolomic approach to unpicking the actions of GHB. J. Neurochem. 2010, 115:58-67.
105. Nevo I., Hamon M. Neurotransmitter and neuromodulatory mechanisms involved in alcohol abuse and alcoholism. Neurochem. Int. 1995, 26:305-336.
106. Nicholson K.L., Balster R.L. GHB: a new and novel drug of abuse. Drug Alcohol Depend. 2001, 63:1-22.
107. Olney J.W. Excitotoxicity: an overview. Can. Dis. Wkly. Rep. 1990, 16(Suppl. 1E):47-57.
108. Olney J.W. Excitotoxicity, apoptosis and neuropsychiatric disorders. Curr. Opin. Pharmacol. 2003, 3:101-109.
109. Orser B.A. Extrasynaptic GABAA receptors are critical targets for sedative-hypnotic drugs. J. Clin. Sleep Med. 2006, 2:S12-S18.
110. Oscar-Berman M., Marinkovic K. Alcohol: effects on neurobehavioral functions and the brain. Neuropsychol. Rev. 2007, 17:239-257.
111. Ottani A., Saltini S., Bartiromo M., Zaffe D., Botticelli A.R., Ferrari A., Bertolini A., Genedani S. Effect of ã-hydroxybutyrate in two rat models of focal cerebral damage. Brain. Res. 2003, 986:181-190.
112. Pan Y.M., Gill G.N., Tilson C.S., Wall W.H., McCurdy H.H. Improved procedure for the analysis of gamma-hydroxybutyrate and ethylene glycol in whole blood. J. Anal. Toxicol. 2001, 25:328-332.
113. Parsons O.A., Nixon S.J. Cognitive functioning in sober social drinkers: a review of the research since 1986. J. Stud. Alcohol 1998, 59:181-190.
114. Pearl P.L., Gibson K.M., Cortez M.A., Wu Y., Carter S.O., Knerr I., Forester K., Pettiford J.M., Jakobs C., Theodore W.H. Succinic semialdehyde dehydrogenase deficiency: lessons from mice and men. J. Inherit. Metab. Dis. 2009, 32:343-352.
115. Pearl P.L., Shamim S., Theodore W.H., Gibson K.M., Forester K., Combs S.E., Lewin D., Dustin I., Reeves-Tyer P., Jakobs C., Sato S. Polysomnographic abnormalities in succinic semialdehyde dehydrogenase (SSADH) deficiency. Sleep 2009, 32:1645-1648.
116. Pedraza C., Garciá F.B., Navarro J.F. Neurotoxic effects induced by gammahydroxybutyric acid (GHB) in male rats. Int. J. Neuropsychopharmacol. 2009, 12:1165-1177.
117. Perez E., Chu J., Bania T. Seven days of gamma-hydroxybutyrate (GHB) use produces severe withdrawal. Ann. Emerg. Med. 2006, 48:219-220.
118. Perouansky M., Hemmings H.C. Neurotoxicity of general anesthetics: cause for concern?. Anesthesiology 2009, 111:1365-1371.
119. Renault F., Formstecher E., Callebaut I., Junier M.P., Chneiweiss H. The multifunctional protein PEA-15 is involved in the control of apoptosis and cell cycle in astrocytes. Biochem. Pharmacol. 2003, 66:1581-1588.
120. Rose M.E., Grant J.E. Alcohol-induced blackout. Phenomenology, biological basis, and gender differences. J. Addict. Med. 2010, 4:61-73.
121. Roth R.H., Giarman N.J. Conversion in vivo of gamma-aminobutyric to gamma-hydroxybutyric acid in the rat. Biochem. Pharmacol. 1969, 18:247-250.
122. Rowland L.M. Subanesthetic ketamine: how it alters physiology and behavior in humans. Aviat. Space Environ. Med. 2005, 76:C52-C58.
123. Ryu M.J., Kim D., Kang U.B., Kim J., Shin H.S., Lee C., Yu M.H. Proteomic analysis of gamma-butyrolactone-treated mouse thalamus reveals dysregulated proteins upon absence seizure. J. Neurochem. 2007, 102:646-656.
124. Sadasivan S., Maher T.J., Quang L.S. ã-Hydroxybutyrate (GHB), ã-butyrolactone (GBL), and 1,4-butanediol (1,4-BD) reduce the volume of cerebral infarction in rodent transient middle cerebral artery occlusion. Ann. N. Y. Acad. Sci. 2006, 1074:537-544.
125. Satomoto M., Satoh Y., Terui K., Miyao H., Takishima K., Ito M., Imaki J. Neonatal exposure to sevoflurane induces abnormal social behaviors and deficits in fear conditioning in mice. Anesthesiology 2009, 110:628-637.
126. Sauer S.W., Kolker S., Hoffmann G.F., Ten Brink H.J., Jakobs C., Gibson K.M., Okun J.G. Enzymatic and metabolic evidence for a region specific mitochondrial dysfunction in brains of murine succinic semialdehyde dehydrogenase deficiency (Aldh5a1-/- mice). Neurochem. Int. 2007, 50:653-659.
127. Schnackenberg B.J., Saini U.T., Robinson B.L., Ali S.F., Patterson T.A. An acute dose of gamma-hydroxybutyric acid alters gene expression in multiple mouse brain regions. Neuroscience 2010, 170:523-541.
128. Schwartz R.H., Milteer R., LeBeau M.A. Drug-facilitated sexual assault ('date rape'). South. Med. J. 2000, 93:558-561.
129. Sgaravatti A.M., Magnusson A.S., Oliveira A.S., Mescka C.P. Effects of 1,4-butanediol administration on oxidative stress in rat brain: study of the neurotoxicity of gamma-hydroxybutyric acid in vivo. Metab. Brain Dis. 2009, 24:271-282.
130. Sgaravatti A.M., Sgarbi M.B., Testa C.G., Durigon K., Pederzolli C.D., Prestes C.C., Wyse A.T., Wannmacher C.M., Wajner M., Dutra-Filho C.S. Gamma-hydroxybutyric acid induces oxidative stress in cerebral cortex of young rats. Neurochem. Int. 2007, 50:564-570.
131. Sircar R., Basak A., Sircar D. Gamma-hydroxybutyric acid-induced cognitive deficits in the female adolescent rat. Ann. N. Y. Acad. Sci. 2008, 1139:386-389.
132. Sircar R., Basak A., Sircar D., Wu L.C. Effects of gamma-hydroxybutyric acid on spatial learning and memory in adolescent and adult female rats. Pharmacol. Biochem. Behav. 2010, 96:187-193.
133. Sircar R., Wu L.C., Reddy K., Sircar D., Basak A.K. GHB-induced cognitive deficits during adolescence and the role of NMDA receptor. Curr. Neuropharmacol. 2011, 9:240-243.
134. Sircar R., Basak A. Adolescent gamma-hydroxybutyric acid exposure decreases cortical N-methyl-d-aspartate receptor and impairs spatial learning. Pharmacol. Biochem. Behav. 2004, 79:701-708.
135. Smith K.M. Drugs used in acquaintance rape. J. Am. Pharm. Assoc. (Wash.) 1999, 39:519-525.
136. Snead O.C., Bearden L.J. Naloxone overcomes the dopaminergic, EEG, and behavioral effects of gamma-hydroxybutyrate. Neurology 1980, 30:832-838.
137. Snead O.C., Furner R., Liu C.C. In vivo conversion of gamma-aminobutyric acid and 1,4-butanediol to gamma-hydroxybutyric acid in rat brain. Studies using stable isotopes. Biochem. Pharmacol. 1989, 38:4375-4380.
138. Snead O.C., Gibson K.M. Gamma-hydroxybutyric acid. N. Engl. J. Med. 2005, 352:2721-2732.
139. Snyder S.H. Phencyclidine. Nature 1980, 285:355-356.
140. Sumnall H.R., Woolfall K., Edwards S., Cole J.C., Beynon C.M. Use, function, and subjective experiences of gamma-hydroxybutyrate (GHB). Drug Alcohol Depend. 2008, 92:286-290.
141. Tapert S.F., Brown G.G., Kindermann S.S., Cheung E.H., Frank L.R., Brown S.A. fMRI measurement of brain dysfunction in alcohol-dependent young women. Alcohol Clin. Exp. Res. 2001, 25:236-245.
142. Tarabar A.F., Nelson L.S. The gamma-hydroxybutyrate withdrawal syndrome. Toxicol. Rev. 2004, 23:45-49.
143. Tunnicliff G. Significance of gamma-hydroxybutyric acid in the brain. Gen. Pharmacol. 1992, 23:1027-1034.
144. van Laar, M., Cruts, A.A., van Ooyen-Houben, M.M., Meyr, R.F., Brunt, T., 2011. Netherlands National Drug Monitor: NDM Annual Report 2009. Trimbos Institute, Utrecht, The Netherlands.
145. van Nieuwenhuijzen P.S., Kashem M.A., Matsumoto I., Hunt G.E., McGregor I.S. A long hangover from party drugs: residual proteomic changes in the hippocampus of rats 8 weeks after gamma-hydroxybutyrate (GHB), 3,4-methylenedioxymethamphetamine (MDMA) or their combination. Neurochem. Int. 2010, 56:871-877.
146. van Noorden M.S., Kamal R., de Jong C.A., Vergouwen A.C., Zitman F.G. Gamma-hydroxybutyric acid (GHB) dependence and the GHB withdrawal syndrome: diagnosis and treatment. Ned. Tijdschr. Geneeskd. 2010, 154:A1286.
147. Van Sassenbroeck D.K., De N.N., De P.P., Belpaire F.M., Verstraete A.G., Calle P.A., Buylaert W.A. Abrupt awakening phenomenon associated with gamma-hydroxybutyrate use: a case series. Clin. Toxicol. (Phila) 2007, 45:533-538.
148. Varela M., Nogue S., Oros M., Miro O. Gamma hydroxybutirate use for sexual assault. Emerg. Med. J. 2004, 21:255-256.
149. Vayer P., Mandel P., Maitre M. Conversion of gamma-hydroxybutyrate to gamma-aminobutyrate in vitro. J. Neurochem. 1985, 45:810-814.
150. Vayer P., Mandel P., Maitre M. Gamma-hydroxybutyrate, a possible neurotransmitter. Life Sci. 1987, 41:1547-1557.
151. Wang D.S., Orser B.A. Inhibition of learning and memory by general anesthetics. Can. J. Anaesth. 2011, 58:167-177.
152. Weerts E.M., Goodwin A.K., Griffiths R.R., Brown P.R., Froestl W., Jakobs C., Gibson K.M. Spontaneous and precipitated withdrawal after chronic intragastric administration of gamma-hydroxybutyrate (GHB) in baboons. Psychopharmacology (Berl.) 2005, 179:678-687.
153. White A.M. What happened? Alcohol, memory blackouts, and the brain. Alcohol Res. Health 2003, 27:186-196.
154. White, A.M., 2004. What happened? Alcohol, Memory Blackouts, and the Brain. National Institute on Alcohol Abuse and Alcoholism. http://pubs.niaaa.nih.gov/publications/arh27-2/186-196.htm.
155. Williams L.C., Keyes C. Psychoactive drugs. Clinical Toxicology 2001, 640-649. WB Sauders Company, Philadelphia. M.D. Ford, K.A. Delaey, L.J. Ling, T. Erickson (Eds.).
156. Wood D.M., Nicolaou M., Dargan P.I. Epidemiology of recreational drug toxicity in a nightclub environment. Subst. Use Misuse 2009, 44:1495-1502.
157. Woolverton W.L., Rowlett J.K., Winger G., Woods J.H., Gerak L.R., France C.P. Evaluation of the reinforcing and discriminative stimulus effects of gamma-hydroxybutyrate in rhesus monkeys. Drug Alcohol Depend. 1999, 54:137-143.
158. Zahr N.M., Kaufman K.L., Harper C.G. Clinical and pathological features of alcohol-related brain damage. Nat. Rev. Neurol. 2011, 7:284-294.
159. Zvosec D.L., Smith S., Porrata T., Strobl A., Dyer J.E. Case series of 226 gamma-hydroxybutyrate-associated deaths: lethal toxicity and trauma. Am. J. Emerg. Med. 2010, 29:319-332.